InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,117.07
(
1.04%
)
US TECH 100
17,353.20
(
1.62%
)
Dow Jones
38,635.43
(
1.07%
)
Brent Oil
83.34
(
-0.35%
)
Bitcoin
61,478.04
(
3.99%
)
Post# of 251696
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119555
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 213091

Monday, 09/11/2017 6:16:36 AM

Monday, September 11, 2017 6:16:36 AM

Post# of 251696
(ACHN/Medivir)—JNJ throws in the towel on HCV:

http://www.prnewswire.com/news-releases/janssen-to-discontinue-hepatitis-c-development-program-643657613.html

Janssen Sciences…today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals - AL-335, odalasvir and simeprevir… This decision was made in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C.

Inevitable and overdue.

Medivir (MVIR-B.ST) is down 8% today in Stockholm, implying that some investors didn’t realize JNJ’s HCV regimen was obsolete.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up